Sodium-Glucose Cotransporter2-inhibitors (SGLT2i) were developed for treating diabetic patients. Empagliflozin and dapagliflozin, frequently prescribed SGLT2i, are now also recommended for nondiabetic patients with heart failure (HF) or chronic-kidney-disease (CKD). Ketoacidosis is one of the SGLT2i-associated adverse events and may manifest also as euglycemic/hypoglycemic ketoacidosis, defined by a blood glucose level <250 mg/dl, β-hydroxybutyrate >3 mmol/L, bicarbonate <18 mmol/L, pH <7.3 and anion gap >10 mmol/L.
